KBC Group NV Buys 883 Shares of Illumina, Inc. (NASDAQ:ILMN)

KBC Group NV lifted its stake in Illumina, Inc. (NASDAQ:ILMN) by 2.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 43,399 shares of the life sciences company’s stock after acquiring an additional 883 shares during the quarter. KBC Group NV’s holdings in Illumina were worth $5,799,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. AQR Capital Management LLC grew its position in Illumina by 390.9% in the 2nd quarter. AQR Capital Management LLC now owns 75,561 shares of the life sciences company’s stock worth $7,887,000 after purchasing an additional 60,168 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of Illumina by 31.8% in the second quarter. The Manufacturers Life Insurance Company now owns 125,285 shares of the life sciences company’s stock worth $13,077,000 after acquiring an additional 30,229 shares during the period. Creative Planning increased its position in Illumina by 3.4% during the second quarter. Creative Planning now owns 16,144 shares of the life sciences company’s stock valued at $1,685,000 after acquiring an additional 525 shares during the last quarter. B. Riley Wealth Advisors Inc. lifted its holdings in Illumina by 176.3% in the second quarter. B. Riley Wealth Advisors Inc. now owns 7,176 shares of the life sciences company’s stock valued at $749,000 after acquiring an additional 4,579 shares during the period. Finally, Truist Financial Corp boosted its position in Illumina by 1.7% in the second quarter. Truist Financial Corp now owns 62,840 shares of the life sciences company’s stock worth $6,559,000 after purchasing an additional 1,075 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Trading Up 1.0 %

Shares of NASDAQ ILMN opened at $133.01 on Friday. Illumina, Inc. has a 1-year low of $100.08 and a 1-year high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The business’s 50 day moving average is $139.05 and its two-hundred day moving average is $135.05. The stock has a market capitalization of $21.10 billion, a P/E ratio of -13.35 and a beta of 1.11.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. Illumina’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.33 EPS. As a group, research analysts expect that Illumina, Inc. will post 4.13 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Royal Bank of Canada increased their price objective on shares of Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a research note on Thursday, October 17th. Morgan Stanley reduced their price objective on Illumina from $156.00 to $150.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Hsbc Global Res upgraded Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price on the stock in a research report on Thursday, October 17th. Finally, Barclays upped their price target on Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Eight equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $165.63.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.